At the NIH Clinical Center in Maryland, 45 healthy adults received an injection of a weakened dengue virus candidate—and researchers followed their immune responses for a full year. The controlled trial offered a close look at a puzzle that makes dengue unusually difficult to prevent: antibodies left by an earlier infection can sometimes help a different strain spread instead of stopping it.
Dengue is carried by Aedes mosquitoes and can cause fever, flu-like symptoms and joint pain. Severe cases can lead to dangerous bleeding and fluid leakage. The virus has four strains, called serotypes. After infection with one, a person may have some protection against that strain, but a later infection with another can be more serious. This risk also complicates vaccine design, because a vaccine that does not create strong enough protection might act like an earlier infection.
In the Phase I trial, participants were 18 to 59 years old. Researchers grouped them by their medical history and by the dengue-neutralizing antibodies in their blood at the start. The groups included people with no known prior dengue exposure, people with one past natural infection involving DENV1, DENV2 or DENV4, and people with evidence of multiple past infections. Everyone received one injection of a weakened DENV3 vaccine candidate in the upper arm.
The team watched participants closely for symptoms and adverse reactions each day for 28 days. They also collected blood samples on a planned schedule from day 0 through day 365, allowing them to compare virus levels and signs of immune activity over time.
The results challenged a simple assumption: that more virus growth and a stronger initial immune attack must lead to better protection. Instead, antibodies that most strongly enhanced dengue infection were linked to the highest virus levels and a delay in early antiviral responses. That response did not last. The protection associated with this strong antibody-driven growth faded quickly, suggesting that an intense early reaction can leave defenses depleted rather than durable.
The more lasting pattern came from balance. Moderate viral replication, paired with early and well-balanced immune control, was associated with stronger, longer-lasting immunity. In other words, the trial points to the timing and quality of the immune response—not simply its size—as important clues to protection.
The findings may help researchers judge whether future dengue vaccines or treatments create useful immune memory without encouraging the virus to multiply. They do not mean that every second dengue infection will become severe, or that the trial tested a finished vaccine for broad use. But by tracking immune responses in people with different infection histories, the NIH study provides a clearer map for the work ahead: protection may depend on teaching the immune system to respond firmly, without tipping into a response that helps the virus first.